Literature DB >> 7525193

Guidelines for the rational use of benzodiazepines. When and what to use.

H Ashton1.   

Abstract

The main actions of benzodiazepines (hypnotic, anxiolytic, anticonvulsant, myorelaxant and amnesic) confer a therapeutic value in a wide range of conditions. Rational use requires consideration of the large differences in potency and elimination rates between different benzodiazepines, as well as the requirements of individual patients. As hypnotics, benzodiazepines are mainly indicated for transient or short term insomnia, for which prescriptions should if possible be limited to a few days, occasional or intermittent use, or courses not exceeding 2 weeks. Temazepam, loprazolam and lormetazepam, which have a medium duration of action are suitable. Diazepam is also effective in single or intermittent dosage. Potent, short-acting benzodiazepines such as triazolam appear to carry greater risks of adverse effects. As anxiolytics, benzodiazepines should generally be used in conjunction with other measures (psychological treatments, antidepressants, other drugs) although such measures have a slower onset of action. Indications for benzodiazepines include acute stress reactions, episodic anxiety, fluctuations in generalised anxiety, and as initial treatment for severe panic and agoraphobia. Diazepam is usually the drug of choice, given in single doses, very short (1 to 7 days) or short (2 to 4 weeks) courses, and only rarely for longer term treatment. Alprazolam has been widely used, particularly in the US, but is not recommended in the UK, especially for long term use. Benzodiazepines also have uses in epilepsy (diazepam, clonazepam, clobazam), anaesthesia (midazolam), some motor disorders and occasionally in acute psychoses. The major clinical advantages of benzodiazepines are high efficacy, rapid onset of action and low toxicity. Adverse effects include psychomotor impairment, especially in the elderly, and occasionally paradoxical excitement. With long term use, tolerance, dependence and withdrawal effects can become major disadvantages. Unwanted effects can largely be prevented by keeping dosages minimal and courses short (ideally 4 weeks maximum), and by careful patient selection. Long term prescription is occasionally required for certain patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525193     DOI: 10.2165/00003495-199448010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  54 in total

1.  The use of low-dose intranasal midazolam to treat panic disorder: a pilot study.

Authors:  E Schweizer; C Clary; A I Dever; L A Mandos
Journal:  J Clin Psychiatry       Date:  1992-01       Impact factor: 4.384

Review 2.  Established anticonvulsants and treatment of refractory epilepsy.

Authors:  M J Brodie
Journal:  Lancet       Date:  1990-08-11       Impact factor: 79.321

3.  Indications and contraindications for chronic anxiolytic treatment: is there tolerance to the anxiolytic effect?

Authors:  K Rickels; W G Case; R W Downing; A Winokur
Journal:  Adv Biochem Psychopharmacol       Date:  1985

4.  Anxiety caused by a short-life hypnotic.

Authors:  K Morgan; I Oswald
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-27

5.  Hypnotics: rebound insomnia and residual sequelae.

Authors:  A N Nicholson
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

6.  Benzodiazepine hypnotics remain effective for 24 weeks.

Authors:  I Oswald; C French; K Adam; J Gilham
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-20

Review 7.  Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines.

Authors:  J B Herman; A W Brotman; J F Rosenbaum
Journal:  J Clin Psychiatry       Date:  1987-10       Impact factor: 4.384

8.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Authors:  J C Ballenger; G D Burrows; R L DuPont; I M Lesser; R Noyes; J C Pecknold; A Rifkin; R P Swinson
Journal:  Arch Gen Psychiatry       Date:  1988-05

Review 9.  High-potency benzodiazepines for short-term management of panic disorder: the U.S. experience.

Authors:  G E Tesar
Journal:  J Clin Psychiatry       Date:  1990-05       Impact factor: 4.384

10.  Chronic use of benzodiazepines and psychomotor and cognitive test performance.

Authors:  I Lucki; K Rickels; A M Geller
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

View more
  68 in total

1.  Initial benzodiazepine use and improved health-related quality of life.

Authors:  Rolf van Hulten; Bart Teeuw; Albert Bakker; Hubert G Leufkens
Journal:  Pharm World Sci       Date:  2005-02

2.  Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.

Authors:  James K Rowlett; Snjezana Lelas; Walter Tornatzky; Stephanie C Licata
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

3.  Time to response in generalized anxiety disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone.

Authors:  Mark Hyman Rapaport; Steve B Skarky; David J Katzelnick; Jeffrey N Dewester; James M Harper; Kay E McCrary
Journal:  Psychiatry (Edgmont)       Date:  2006-12

4.  Effect of concomitant use of benzodiazepines and other drugs on the risk of injury in a veterans population.

Authors:  Dustin D French; Thomas N Chirikos; Andrea Spehar; Robert Campbell; Heidi Means; Tatjana Bulat
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia disease.

Authors:  Wei Xiong; Shao-Rui Chen; Liming He; Kejun Cheng; Yi-Lin Zhao; Hong Chen; De-Pei Li; Gregg E Homanics; John Peever; Kenner C Rice; Ling-gang Wu; Hui-Lin Pan; Li Zhang
Journal:  Nat Neurosci       Date:  2014-01-05       Impact factor: 24.884

6.  Influence of inflammatory nociception on the anxiolytic-like effect of diazepam and buspirone in rats.

Authors:  A Fernández-Guasti; R Reyes; L Martínez-Mota; F J López-Muñoz
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

7.  Patterns of psychotropic medication prescriptions by psychiatrists for private clinic outpatients in kerman province, iran.

Authors:  Abdolreza Sabahi; Gholamreza Sepehri; Mottahareh Mohsenbeigi; Ehsan Sepehri
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24

8.  Effects of pregabalin in patients with hypnotic-dependent insomnia.

Authors:  Youg Won Cho; Mei Ling Song
Journal:  J Clin Sleep Med       Date:  2014-05-15       Impact factor: 4.062

9.  A drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital.

Authors:  Karan B Thakkar; Mangal M Jain; Gauri Billa; Abhijit Joshi; Akash A Khobragade
Journal:  J Clin Diagn Res       Date:  2013-12-15

10.  Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study.

Authors:  Jolyce Bourgeois; Monique M Elseviers; Luc Van Bortel; Mirko Petrovic; Robert H Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  2014-08-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.